These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 18079739)

  • 21. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
    Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
    Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An inhibitor of Janus kinase 2 prevents polycythemia in mice.
    Mathur A; Mo JR; Kraus M; O'Hare E; Sinclair P; Young J; Zhao S; Wang Y; Kopinja J; Qu X; Reilly J; Walker D; Xu L; Aleksandrowicz D; Marshall G; Scott ML; Kohl NE; Bachman E
    Biochem Pharmacol; 2009 Aug; 78(4):382-9. PubMed ID: 19413997
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proteomic study of the impact of the JAK2-V617F mutation on the phenotype of essential thrombocythemia.
    Mossuz P; Arlotto M; Hermouet S; Bouamrani A; Lippert E; Girodon F; Dobo I; Vincent P; Cahn JY; Berger F
    Exp Hematol; 2008 Dec; 36(12):1642-7. PubMed ID: 18838204
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A sensitive and reliable semi-quantitative real-time PCR assay to detect JAK2 V617F in blood.
    Poodt J; Fijnheer R; Walsh IB; Hermans MH
    Hematol Oncol; 2006 Dec; 24(4):227-33. PubMed ID: 17006961
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
    Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H; Bock O
    Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Constitutive JunB expression, associated with the JAK2 V617F mutation, stimulates proliferation of the erythroid lineage.
    da Costa Reis Monte-Mór B; Plo I; da Cunha AF; Costa GG; de Albuquerque DM; Jedidi A; Villeval JL; Badaoui S; Lorand-Metze I; Pagnano KB; Saad ST; Vainchenker W; Costa FF
    Leukemia; 2009 Jan; 23(1):144-52. PubMed ID: 18843287
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
    Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
    Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
    [TBL] [Abstract][Full Text] [Related]  

  • 28. JAK2 V617F/C618R mutation in a patient with polycythemia vera: a case study and review of the literature.
    Yoo JH; Park TS; Maeng HY; Sun YK; Kim YA; Kie JH; Cho EH; Song J; Lee KA; Suh B; Choi JR
    Cancer Genet Cytogenet; 2009 Feb; 189(1):43-7. PubMed ID: 19167611
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation.
    Aboudola S; Murugesan G; Szpurka H; Ramsingh G; Zhao X; Prescott N; Tubbs RR; Maciejewski JP; Hsi ED
    Am J Surg Pathol; 2007 Feb; 31(2):233-9. PubMed ID: 17255768
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dasatinib inhibits progenitor cell proliferation from polycythaemia vera.
    Wappl M; Jaeger E; Streubel B; Gisslinger H; Schwarzinger I; Valent P; Oehler L
    Eur J Clin Invest; 2008 Aug; 38(8):578-84. PubMed ID: 18717827
    [TBL] [Abstract][Full Text] [Related]  

  • 31. JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms.
    Oh ST; Gotlib J
    Expert Rev Hematol; 2010 Jun; 3(3):323-37. PubMed ID: 21082983
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Frequency and clinical features of the JAK2 V617F mutation in pediatric patients with sporadic essential thrombocythemia.
    Nakatani T; Imamura T; Ishida H; Wakaizumi K; Yamamoto T; Otabe O; Ishigami T; Adachi S; Morimoto A
    Pediatr Blood Cancer; 2008 Dec; 51(6):802-5. PubMed ID: 18802948
    [TBL] [Abstract][Full Text] [Related]  

  • 33. JAK2 V617F uses distinct signalling pathways to induce cell proliferation and neutrophil activation.
    Oku S; Takenaka K; Kuriyama T; Shide K; Kumano T; Kikushige Y; Urata S; Yamauchi T; Iwamoto C; Shimoda HK; Miyamoto T; Nagafuji K; Kishimoto J; Shimoda K; Akashi K
    Br J Haematol; 2010 Aug; 150(3):334-44. PubMed ID: 20553273
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients.
    Pardanani A; Lasho T; Smith G; Burns CJ; Fantino E; Tefferi A
    Leukemia; 2009 Aug; 23(8):1441-5. PubMed ID: 19295546
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Givinostat and hydroxyurea synergize in vitro to induce apoptosis of cells from JAK2(V617F) myeloproliferative neoplasm patients.
    Amaru Calzada A; Pedrini O; Finazzi G; Leoni F; Mascagni P; Introna M; Rambaldi A; Golay J;
    Exp Hematol; 2013 Mar; 41(3):253-60.e2. PubMed ID: 23111067
    [TBL] [Abstract][Full Text] [Related]  

  • 36. JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms.
    Duletić AN; Dekanić A; Hadzisejdić I; Kusen I; Matusan-Ilijas K; Grohovac D; Grahovac B; Jonjić N
    Coll Antropol; 2012 Sep; 36(3):859-65. PubMed ID: 23213945
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F.
    Boissinot M; Cleyrat C; Vilaine M; Jacques Y; Corre I; Hermouet S
    Oncogene; 2011 Feb; 30(8):990-1001. PubMed ID: 21042281
    [TBL] [Abstract][Full Text] [Related]  

  • 38. JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets.
    Toyama K; Karasawa M; Yamane A; Irisawa H; Yokohama A; Saitoh T; Handa H; Matsushima T; Sawamura M; Miyawaki S; Murakami H; Nojima Y; Tsukamoto N
    Br J Haematol; 2007 Oct; 139(1):64-9. PubMed ID: 17854308
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Polycythemia vera: scientific advances and current practice.
    Tefferi A; Spivak JL
    Semin Hematol; 2005 Oct; 42(4):206-20. PubMed ID: 16210034
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
    Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.